X
GO

Dr. Michele Carbone's Scientific Publications

Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma

Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma

Oncogene - Short Communication

Germline BAP1 mutations predispose to several cancers, in particular malignant mesothelioma. Mesothelioma is an aggressive malignancy generally associated with professional exposure to asbestos. However, to date, we found that none of the mesothelioma patients carrying germline BAP1 mutations were professionally exposed to asbestos
0 Comments
HMGB1 and its hyper-acetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients

HMGB1 and its hyper-acetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients

This study shows that hyper-acetylated HMGB1 is an accurate biomarker to differentiate malignant mesothelioma patients from individuals occupationally exposed to asbestos and unexposed controls. A trial to independently validate these findings will start soon.
0 Comments
Combined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700s

Combined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700s

Our multinational team discovered that four apparently unrelated US families share a common ancestor, a couple who immigrated from Germany in the early 1700s. 
0 Comments
Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies

Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies

Online journal: Expert Review of Respiratory Medicine

Malignant mesothelioma is an aggressive cancer whose pathogenesis is causally linked to occupational exposure to asbestos. Familial clusters of mesotheliomas have been observed in settings of genetic predisposition. Mesothelioma incidence is anticipated to increase worldwide in the next two decades. Novel treatments are needed, as current treatment modalities may improve the quality of life, but have shown modest effects in improving overall survival. Increasing knowledge on the molecular characteristics of mesothelioma has led to the development of novel potential therapeutic strategies, including: molecular targeted approaches, that is the inhibition of vascular endothelial growth factor with bevacizumab; immunotherapy with chimeric monoclonal antibody, immunotoxin, antibody drug conjugate, vaccine and viruses; inhibition of asbestos-induced inflammation, that is aspirin inhibition of HMGB1 activity may decrease or delay mesothelioma onset and/or growth. We elaborate on the rationale behind new therapeutic strategies, and summarize available preclinical and clinical results, as well as efforts still ongoing. 

Authors: Angela Bononi, Andrea Napolitano, Harvey I Pass, Haining Yang, and Michele Carbone

0 Comments
Aspirin may delay growth of asbestos-related cancer

Aspirin may delay growth of asbestos-related cancer

Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression

Aspirin (acetylsalicylic acid, ASA) is the most widely used nonsteriodial anti-inflammatory drug that reduces the incidence, metastatic potential and mortality of many inflammation-induced cancers.  Can it play a role in helping patients with malignant mesothelioma?
0 Comments
RSS
123456